Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma DOI Open Access
Jun Ho Ji, Sang Yun Ha, Danbi Lee

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(8), P. 7640 - 7640

Published: April 21, 2023

Hepatocellular carcinoma (HCC) has one of the highest mortality rates among solid cancers. Late diagnosis and a lack efficacious treatment options contribute to dismal prognosis HCC. Immune checkpoint inhibitor (ICI)-based immunotherapy presented new milestone in cancer. Immunotherapy yielded remarkable responses range cancer types including Based on therapeutic effect ICI alone (programmed cell death (PD)-1/programmed death-ligand1 (PD-L)1 antibody), investigators have developed combined therapies + ICI, tyrosine kinase (TKI), locoregional or novel immunotherapy. Although these regimens demonstrated increasing efficacy with addition drugs, development biomarkers predict toxicity response patients receiving is urgent need. PD-L1 expression tumor cells received most attention early studies various predictive biomarkers. However, limited utility as biomarker Accordingly, subsequent evaluated mutational burden (TMB), gene signatures, multiplex immunohistochemistry (IHC) In this review, we aim discuss current state for HCC, results studies, future direction.

Language: Английский

Enzyme-responsive, multi-lock optical probes for molecular imaging and disease theranostics DOI
Penghui Cheng, Kanyi Pu

Chemical Society Reviews, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 1, 2024

Enzyme-responsive, multi-lock optical probes exhibit superior detection specificity towards certain biomolecular events and pathological conditions, offering high disease diagnostic accuracy treatment efficacy.

Language: Английский

Citations

11
Tumour organoids and assembloids: Patient‐derived cancer avatars for immunotherapy DOI Creative Commons
Jie Mei, Xingjian Liu, Huixiang Tian

et al.

Clinical and Translational Medicine, Journal Year: 2024, Volume and Issue: 14(4)

Published: April 1, 2024

Abstract Background Organoid technology is an emerging and rapidly growing field that shows promise in studying organ development screening therapeutic regimens. Although organoids have been proposed for a decade, concerns exist, including batch‐to‐batch variations, lack of the native microenvironment clinical applicability. Main body The concept has derived patient‐derived tumour (PDTOs) personalized drug new discovery, mitigating risks medication misuse. greater similarity between PDTOs primary tumours, more influential model will be. Recently, ‘tumour assembloids’ inspired by cell‐coculture attracted attention to complement current PDTO technology. High‐quality must reassemble critical components, multiple cell types, matrix, paracrine factors, angiogenesis microorganisms. This review begins with brief overview history PDTOs, followed approaches generating assembloids. Personalized practised; however, it remains unclear whether can predict immunotherapies, immune drugs (e.g. checkpoint inhibitors) cells tumour‐infiltrating lymphocyte, T receptor‐engineered chimeric antigen receptor‐T cell). as cancer avatars patients, be expanded stored form biobank. Conclusion Fundamental research trials are ongoing, intention use these models replace animals. Pre‐clinical immunotherapy using beneficial patients. Key Points not yet constructed key cellular non‐cellular components. should expandable editable. promising preclinical unless mature established. biobanks consensual standards urgently needed.

Language: Английский

Citations

9
Therapeutic potential of anti-ErbB3 chimeric antigen receptor natural killer cells against breast cancer DOI Creative Commons
J.H. Lee,

Jinhoo Song,

Wonbeak Yoo

et al.

Cancer Immunology Immunotherapy, Journal Year: 2025, Volume and Issue: 74(2)

Published: Jan. 3, 2025

ErbB3 is markedly overexpressed in breast cancer cells and associated with resistance metastasis. Additionally, expression levels are positively correlated low densities of tumor-infiltrating lymphocytes, a marker poor prognosis. Consequently, promising therapeutic target for immunotherapy. Here, we report the generation ErbB3-targeted chimeric antigen receptor (CAR)-modified natural killer (NK) by transducing cord blood-derived primary NK using vsv-g envelope-pseudotyped lentiviral vectors. Transduced displayed stable CAR-expressing activity increased cytotoxicity against ErbB3-positive cell lines. Furthermore, anti-ErbB3 (aErbB3) CAR-NK strongly reduced tumor burden SK-BR-3 xenograft mouse model without observable side effects. These findings underscore potential aErbB3 as targeted immunotherapy cancer, suggesting alternative to conventional treatments.

Language: Английский

Citations

1
Prognostic value of the pretreatment Naples prognostic score in patients with colorectal cancer: a systematic review and meta-analysis DOI Creative Commons

Hui Liu,

Dongwang Zhu,

Dequan Jiang

et al.

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 14

Published: Jan. 7, 2025

The prognostic significance of the Naples score (NPS) in colorectal cancer remains uncertain. This study aims to investigate correlation between pretreatment NPS and long-term oncological outcomes patients with cancer. A comprehensive literature search electronic databases, including PubMed, Embase, Web Science, was conducted up July 1st, 2024. primary assessed were survival outcomes. Subgroup analysis sensitivity performed during pooled analysis. Eight studies 2571 included. results indicated that high group exhibited significantly worse overall (HR= 2.08 95%CI: 1.74-2.48; P<0.01; I2 = 0%) disease-free (HR=2.03; 1.49-2.77; 30%). Notably, on both consistent across different geographical regions, tumor stages, treatments examined this study. Furthermore, analyses confirmed robustness these combined results. could serve as a valuable biomarker for predicting diagnosed

Language: Английский

Citations

1
DNA origami-based composite nanosandwich for iteratively potentiated chemo-immunotherapy DOI
Mengyue Li, Hanxi Zhang,

Peizheng Xiong

et al.

Journal of Controlled Release, Journal Year: 2025, Volume and Issue: 379, P. 452 - 465

Published: Jan. 17, 2025

Language: Английский

Citations

1
Systematic inference of super-resolution cell spatial profiles from histology images DOI Creative Commons
Peng Zhang, Chaofei Gao, Zhuoyu Zhang

et al.

Nature Communications, Journal Year: 2025, Volume and Issue: 16(1)

Published: Feb. 21, 2025

Inferring cell spatial profiles from histology images is critical for cancer diagnosis and treatment in clinical settings. In this study, we report a weakly-supervised deep-learning method, HistoCell, to directly infer super-resolution consisting of types, states their network at the single-nucleus-level. Benchmark analysis demonstrates that HistoCell robustly achieves state-of-the-art performance terms type/states prediction solely across multiple tissues. can significantly enhance deconvolution accuracy transcriptomics data enable accurate annotation subtle tissue architectures. Moreover, applied de novo discovery clinically relevant organization indicators, including prognosis drug response biomarkers, diverse types. also image-based screening populations drives phenotype interest, discover population corresponding indicators associated with gastric malignant transformation risk. Overall, emerges as powerful versatile tool studies image-only cohorts. The significance inferring patients remains be explored. Here, authors develop direct

Language: Английский

Citations

1
Exploring Immune Checkpoint Inhibitors: Focus on PD-1/PD-L1 Axis and Beyond DOI
Durre Aden, Samreen Zaheer, Niti Sureka

et al.

Pathology - Research and Practice, Journal Year: 2025, Volume and Issue: 269, P. 155864 - 155864

Published: March 1, 2025

Language: Английский

Citations

1
Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer DOI Open Access
L. Pabst, Sébastien Lopes,

Basil Bertrand

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(8), P. 7577 - 7577

Published: April 20, 2023

The therapeutic algorithm of lung cancer has recently been revolutionized by the emergence immune checkpoint inhibitors. However, an objective and durable response rate remains low with those recent therapies some patients even experience severe adverse events. Prognostic predictive biomarkers are therefore needed in order to select who will respond. Nowadays, only validated biomarker is PD-L1 expression, but its value imperfect, it does not offer any certainty a sustained treatment. With progresses molecular biology, genome sequencing techniques, understanding microenvironment tumor host, new features have highlighted. There evidence favor positive mutational burden, as example. From expression interactions within cells circulating peripheral blood, many markers identified associated immunotherapy. In this review, we would like summarize latest knowledge about prognostic inhibitors efficacy go further field precision immuno-oncology.

Language: Английский

Citations

21
Oncometabolite 2-hydroxyglutarate regulates anti-tumor immunity DOI Creative Commons
Mengyuan Cai, Jianyi Zhao, Qiang Ding

et al.

Heliyon, Journal Year: 2024, Volume and Issue: 10(2), P. e24454 - e24454

Published: Jan. 1, 2024

"Oncometabolite" 2-hydroxyglutarate (2-HG) is an aberrant metabolite found in tumor cells, exerting a pivotal influence on progression. Recent studies have unveiled its impact the proliferation, activation, and differentiation of anti-tumor T cells. Moreover, 2-HG regulates function innate immune components, including macrophages, dendritic natural killer complement system. Elevated levels hinder α-KG-dependent dioxygenases (α-KGDDs), contributing to tumorigenesis by disrupting epigenetic regulation, genome integrity, hypoxia-inducible factors (HIF) signaling, cellular metabolism. The chiral molecular structure produces two enantiomers: D-2-HG L-2-HG, each with distinct origins biological functions. Efforts inhibit leverage potential L-2-HG demonstrated efficacy cancer immunotherapy. This review delves into metabolism, functions, impacts microenvironment (TIME) 2-HG, providing comprehensive exploration intricate relationship between antitumor immunity. Additionally, we examine clinical applications targeted therapy for highlighting recent breakthroughs as well existing challenges.

Language: Английский

Citations

8
Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy DOI Creative Commons
Xiaojing Qin, Wenjing Ning, Han Liu

et al.

Acta Pharmaceutica Sinica B, Journal Year: 2024, Volume and Issue: 14(6), P. 2361 - 2377

Published: March 24, 2024

T cell-redirecting bispecific antibodies are specifically designed to bind tumor-associated antigens, thereby engaging with CD3 on the cell receptor. This linkage between tumor cells and actively triggers activation initiates targeted killing of identified cells. These have emerged as one most promising avenues within immunotherapy. However, despite success in treating hematological malignancies, significant advancements solid tumors yet be explored. In this review, we aim address critical challenges associated explore novel strategies overcome these obstacles, ultimate goal expanding application therapy include tumors.

Language: Английский

Citations

8